Evidence map›Paper›PMID 28276779›Full record

ReviewUpsala journal of medical sciences2017

Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedside.

Sten-Magnus Aquilonius, Dag Nyholm

Abstract readHistorical ArticleReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Upsala journal of medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Four main therapeutic keys for Parkinson's disease: A mini review.Iranian journal of basic medical sciences · 2019
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sten-Magnus Aquiloniusa Department of Neuroscience , Neurology, Uppsala University , Uppsala , Sweden.
Dag Nyholma Department of Neuroscience , Neurology, Uppsala University , Uppsala , Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review will illustrate the process of moving from an idea through preclinical research and Galenic developments into clinical investigations and finally to approval by regulatory agencies within the European Union. The two new treatment strategies described, levodopa/carbidopa intestinal gel and levodopa/carbidopa microtablets, for advanced Parkinson's disease, have been developed in collaborative research within departments at Uppsala University. With this historical approach, reference priority is given to reports considered to be of special importance for this more than two decades long process 'from bedside to bench to bedside'.

Indexed as

AnimalsCarbidopaCentral Nervous SystemDrug ApprovalDrug CombinationsDrug Delivery SystemsDrug DesignEuropean UnionGelsHistory, 20th CenturyHistory, 21st CenturyHumansLevodopaParkinson DiseaseRandomized Controlled Trials as TopicTabletsCarbidopacarbidopa, levodopa drug combinationDrug CombinationsGelsLevodopaTabletsCarbidopadrug developmentintestinal gellevodopamicrotabletsParkinson’s disease

Identifiers

PMID28276779
PMCPMC5441375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.